Ken Griffin Immuneering Corp Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Immuneering Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 1,882,200 shares of IMRX stock, worth $2.69 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,882,200
Previous 2,078,092
9.43%
Holding current value
$2.69 Million
Previous $15.3 Million
64.39%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding IMRX
# of Institutions
52Shares Held
11.6MCall Options Held
0Put Options Held
0-
Cormorant Asset Management, LP Boston, MA3.3MShares$4.71 Million0.55% of portfolio
-
Black Rock Inc. New York, NY1.38MShares$1.97 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.2MShares$1.72 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD910KShares$1.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA463KShares$661,4030.0% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $37.7M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...